Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 262 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly... August 31, 2020 Helping Kids Cope With Cancer: “Your Stories” Podcast January 11, 2021 Steroids May Limit the Effectiveness of Immunotherapy for Brain Cancer December 28, 2020 Firefighter Advocates For Men’s Health While He Battles Breast Cancer In... September 22, 2021 Load more HOT NEWS Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients... Foodie Friday: Pumpkin EVERYTHING! For Childhood Eye Cancer, Researchers Investigating “Packaged” CAR T Cells Company Gives Cancer Patient a New HVAC System After Treatment and...
